GlassScriptPhysician profile
Noah K Yoshida
NPI 1114651254
$419.84
in general payments reported to CMS, 2019-2025
13 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $149 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $66.40 | 2024-2025 | Krystexxa, Evenity, Tepezza |
| Organon LLC | $56.22 | 2025 | Nexplanon |
| Inspire Medical Systems, INC. | $50.69 | 2025 | Inspire |
| Abbvie INC. | $48.67 | 2025 | |
| Boston Scientific Corporation | $39.50 | 2024-2025 | Watchman Access System, General - Pain Management |
| Astrazeneca Pharmaceuticals LP | $39.12 | 2025 | Farxiga, Airsupra |
| Ibsa Pharma INC. | $21.29 | 2025 | Tirosint, Flector, Licart |
| Grifols USA, LLC | $20.22 | 2025 | Prolastin-C Liquid |
| Daiichi Sankyo INC. | $18.31 | 2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.83 | 2024 | Synjardy, Jardiance |
| Lilly USA, LLC | $14.80 | 2024 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $13.48 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Medtronic, INC. | $13.31 | 2024 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noah Yoshida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.